A research to study if yoga therapy in addition to allergy tablets in urticaria is effective or not

Effectiveness of yoga as an adjunctive to H1 antihistamines in the management of chronic spontaneous urticaria : A randomized controlled open label trial .

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036716

Enrollment

Registered

2021-09-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: Yoga Therapy with antihistamines (Tab. Cetrizine 10mg/day to a maximum of 40mg/day based on standard updosing guidelines): Structured yoga therapy - 6 supervised sessions, each lasting

Eligibility

Inclusion criteria

Inclusion criteria: Consecutive consenting patients of both gender aged 18-60 years, attending the â??Chronic Urticaria clinicâ?? of the dermatology OPD of JIPMER diagnosed with chronic spontaneous urticaria, characterized by the presence of continuous or recurrent wheals with or without angioedema of greater than 6 weeks duration.

Exclusion criteria

Exclusion criteria: Subjects on any medication other than antihistamines for the past three months prior to recruitment Physical urticaria and urticarial vasculitis Pregnant and lactating women Pre-existing endocrine disorders Pre-existing psychiatric illness Pre-existing chronic illness like diabetes, hypertension, hepatic and renal disease, connective tissue diseases, malignancies Other inflammatory skin diseases like psoriasis, lichen planus, vitiligo, pityriasis rubra pilaris, erythroderma

Design outcomes

Primary

Measure	Time frame
Urticaria activity score [UAS7],urticaria control test (UCT),urticaria severity score (USS) and chronic urticaria quality of life score (CU-Q2oL)Timepoint: 0, 1, 2, 3 months	—

Secondary

Measure	Time frame
Heart rate variabilityTimepoint: 0, 3 months;Mediation use[Tab Cetirizine]Timepoint: 0, 1, 2, 3 months;Serum levels of dehydrepiandrosterone sulphate (DHEAS), cortisol, interleukin (IL) 6, IL 18 and neuropeptide YTimepoint: 0, 3 months;sleep score-Pittsburg Sleep Quality Index[PQSI]Timepoint: 0, 1, 2, 3 months;Stress score - Perceived Stress Scale 10 item scale (PSS-10)Timepoint: 0, 1, 2, 3 months	—

Measure

Time frame

Heart rate variabilityTimepoint: 0, 3 months;Mediation use[Tab Cetirizine]Timepoint: 0, 1, 2, 3 months;Serum levels of dehydrepiandrosterone sulphate (DHEAS), cortisol, interleukin (IL) 6, IL 18 and neuropeptide YTimepoint: 0, 3 months;sleep score-Pittsburg Sleep Quality Index[PQSI]Timepoint: 0, 1, 2, 3 months;Stress score - Perceived Stress Scale 10 item scale (PSS-10)Timepoint: 0, 1, 2, 3 months

—

Countries

India

Contacts

Public ContactM MALATHI

JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH PUDUCHERRY

mmalathi.dr@live.com7373842888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026